{"organizations": [], "uuid": "e9feb786a58809d6eecaed0e04917fd10cfcff5d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/8", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/19/business-wire-kala-pharmaceuticals-to-report-fourth-quarter-and-full-year-2017-financial-results-and-host-conference-call.html", "country": "US", "domain_rank": 767, "title": "Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T15:00:00.000+02:00", "replies_count": 0, "uuid": "e9feb786a58809d6eecaed0e04917fd10cfcff5d"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/19/business-wire-kala-pharmaceuticals-to-report-fourth-quarter-and-full-year-2017-financial-results-and-host-conference-call.html", "ord_in_thread": 0, "title": "Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call", "locations": [], "entities": {"persons": [{"name": "kala", "sentiment": "none"}], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "waltham", "sentiment": "none"}], "organizations": [{"name": "kala pharmaceuticals", "sentiment": "negative"}, {"name": "kala pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}, {"name": "about kala pharmaceuticals, inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "WALTHAM, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will release fourth quarter and full year 2017 financial results on Monday, March 26, 2018. Kala will host a live conference call and webcast at 8:00 AM ET to provide a general business update and discuss the Company’s 2017 financial results.\nThe dial-in numbers to access the conference call are 866-300-4091 for domestic callers and 703-736-7433 for international callers. The conference ID is 7082747. To access a live webcast and subsequent archived recording of the call, please visit the “Investors & Media” section on the Kala website at http://kalarx.com/ .\nAbout Kala Pharmaceuticals, Inc.\nKala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180319005365/en/\nInvestors and Media :\nMacDougall Biomedical Communications\nCammy Duong, 781-591-3443\ncduong@macbiocom.com\nSource: Kala Pharmaceuticals, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fkalarx.com%2F&esheet=51775165&newsitemid=20180319005365&lan=en-US&anchor=http%3A%2F%2Fkalarx.com%2F&index=1&md5=0aa916dc396e4da283fc14649af7f654", "http://kalarx.com/", "https://www.businesswire.com/news/home/20180319005365/en/"], "published": "2018-03-19T15:00:00.000+02:00", "crawled": "2018-03-19T16:47:57.006+02:00", "highlightTitle": ""}